سعر روتاركس لقاح بالفم 1.5 مل 2024

Live attenuated human rotavirus vaccine, oral, single 1.5 ml dose, by GlaxoSmithKline (distributor/agent Modern Pharma).

• Prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, G9) when given as a 2-dose series, in infants 6 weeks up to 24 weeks of age.Population: Infants 6-24 weeksDailyMed (NLM)

• Common (≥5%) solicited reactions: fussiness/irritability, cough/runny nose, fever, loss of appetite and vomiting.International label, same product · DailyMed (NLM)

• History of hypersensitivity to the vaccine or any component; infants with hypersensitivity symptoms after a dose should not receive further doses.International label, same product · DailyMed (NLM)
• Uncorrected congenital malformation of the gastrointestinal tract (e.g. Meckel diverticulum) predisposing to intussusception.International label, same product · DailyMed (NLM)
• History of intussusception.International label, same product · DailyMed (NLM)

• Delay vaccination in infants with acute diarrhoea or vomiting; safety and effectiveness not evaluated in chronic gastrointestinal disorders.International label, same product · DailyMed (NLM)
• Safety and effectiveness not established in infants with known primary or secondary immunodeficiencies (including HIV); immunosuppressive therapies may reduce the immune response.International label, same product · DailyMed (NLM)
• Vaccine virus is shed in stool (peak around day 7) and can be transmitted to contacts; caution with immunocompromised close contacts.International label, same product · DailyMed (NLM)

• Rotavirus vaccine, live attenuated (human 89-12 strain, G1P[8]): Live attenuated human rotavirus that replicates in the small intestine and induces immunity; exact protective mechanism unknown (US label).